{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T21:00:03Z","timestamp":1780088403159,"version":"3.54.0"},"reference-count":48,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.jaad.2015.07.053","type":"journal-article","created":{"date-parts":[[2015,10,19]],"date-time":"2015-10-19T00:38:52Z","timestamp":1445215132000},"page":"S82-S88","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":53,"special_numbering":"S1","title":["Treatment of hidradenitis suppurativa with biologic medications"],"prefix":"10.1016","volume":"73","author":[{"given":"Robert A.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel B.","family":"Eisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2015.07.053_bib1","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/jdv.12966","article-title":"European S1 guideline for the treatment of hidradenitis suppurativa\/acne inversa","volume":"29","author":"Zouboulis","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2015.07.053_bib2","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1124\/jpet.301.2.418","article-title":"Binding and functional comparisons of two types of tumor necrosis factor antagonists","volume":"301","author":"Scallon","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jaad.2015.07.053_bib3","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1365-2133.2005.07067.x","article-title":"Etanercept: effective in the management of hidradenitis suppurativa","volume":"154","author":"Cusack","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2015.07.053_bib4","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1111\/j.1365-2133.2007.08372.x","article-title":"An open-label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa","volume":"158","author":"Giamarellos-Bourboulis","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2015.07.053_bib5","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2340\/00015555-0545","article-title":"Etanercept for the treatment of hidradenitis suppurativa","volume":"89","author":"Sotiriou","year":"2009","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2015.07.053_bib6","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.jaad.2008.11.898","article-title":"A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa","volume":"60","author":"Lee","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2015.07.053_bib7","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/archdermatol.2010.72","article-title":"Treatment of hidradenitis suppurativa with etanercept injection","volume":"146","author":"Adams","year":"2010","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2015.07.053_bib8","first-page":"243","article-title":"Impact of TNF-alpha antagonists on the quality of life in selected skin diseases","volume":"148","author":"Gisondi","year":"2013","journal-title":"G Ital Dermatol Venereol"},{"key":"10.1016\/j.jaad.2015.07.053_bib9","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jaad.2009.06.050","article-title":"Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial","volume":"62","author":"Grant","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2015.07.053_bib10","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1365-2133.2011.10339.x","article-title":"A double-blind placebo-controlled randomized trial of adalimumab in the treatment of hidradenitis suppurativa","volume":"165","author":"Miller","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2015.07.053_bib11","doi-asserted-by":"crossref","first-page":"846","DOI":"10.7326\/0003-4819-157-12-201212180-00004","article-title":"Adalimumab for the treatment of moderate to severe hidradenitis suppurativa: a parallel randomized trial","volume":"157","author":"Kimball","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaad.2015.07.053_bib12","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1111\/j.1468-3083.2011.04123.x","article-title":"Experience with ustekinumab for the treatment of moderate to severe hidradenitis suppurativa","volume":"26","author":"Gulliver","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2015.07.053_bib13","doi-asserted-by":"crossref","first-page":"320","DOI":"10.2340\/00015555-1229","article-title":"Management of recalcitrant hidradenitis suppurativa with ustekinumab","volume":"92","author":"Sharon","year":"2012","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2015.07.053_bib14","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1136\/annrheumdis-2012-202392","article-title":"Successful long-term triple disease control by ustekinumab in a patient with Beh\u00e7et's disease, psoriasis and hidradenitis suppurativa","volume":"72","author":"Baerveldt","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2015.07.053_bib15","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.ad.2013.09.011","article-title":"Ustekinumab for hidradenitis suppurativa: a case report","volume":"105","author":"Santos-P\u00e9rez","year":"2014","journal-title":"Actas Dermosifiliogr"},{"key":"10.1016\/j.jaad.2015.07.053_bib16","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3109\/03009742.2010.493895","article-title":"Small-area variations in sales of TNF inhibitors in Sweden between 2000 and 2009","volume":"40","author":"Neovius","year":"2011","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.jaad.2015.07.053_bib17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/jdv.12438","article-title":"Use of biological treatments in patients with hidradenitis suppurativa","volume":"29","author":"Martin-Ezquerra","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1016\/j.jaad.2015.07.053_bib18","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3899\/jrheum.090074","article-title":"Anakinra for rheumatoid arthritis: a systematic review","volume":"36","author":"Mertens","year":"2009","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2015.07.053_bib19","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jaad.2010.12.025","article-title":"Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)\u2014a new autoinflammatory syndrome distinct from PAPA syndrome","volume":"66","author":"Braun-Falco","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2015.07.053_bib20","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1001\/jamadermatol.2013.5377","article-title":"Successful treatment of severe hidradenitis suppurativa with anakinra","volume":"149","author":"Zarchi","year":"2013","journal-title":"JAMA Dermatol"},{"issue":"5 pt 1","key":"10.1016\/j.jaad.2015.07.053_bib21","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0151-9638(06)77566-4","article-title":"Fatal epidermoid carcinoma in hidradenitis suppurativa following treatment with infliximab","volume":"133","author":"Maalouf","year":"2006","journal-title":"Ann Dermatol Venereol"},{"key":"10.1016\/j.jaad.2015.07.053_bib22","first-page":"799","article-title":"Fatal pneumococcal sepsis in patient with hidradenitis suppurative treated with infliximab","volume":"131","author":"Benitez-Macias","year":"2008","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.jaad.2015.07.053_bib23","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1365-2133.2011.10328.x","article-title":"New-onset polyarthritis during successful treatment of hidradenitis suppurativa with infliximab","volume":"165","author":"van Rappard","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2015.07.053_bib24","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1111\/tri.12185","article-title":"Fulminant hepatic failure necessitating transplantation following the initiation of infliximab therapy: a cautionary tale times two","volume":"26","author":"Rowe","year":"2013","journal-title":"Transpl Int"},{"key":"10.1016\/j.jaad.2015.07.053_bib25","first-page":"3","article-title":"A case of a patient with stage III familial hidradenitis suppurativa treated with 3 courses of infliximab and died of metastatic squamous cell carcinoma","volume":"20","author":"Scheinfeld","year":"2014","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.jaad.2015.07.053_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2015.01.020","article-title":"New onset of articular inflammatory manifestations in patients with hidradenitis suppurativa under treatment with infliximab","author":"Acquacalda","year":"2015","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.jaad.2015.07.053_bib27","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/sj.eye.6703100","article-title":"Bilateral Candida chorioretinitis following etanercept treatment for hidradenitis suppurativa","volume":"22","author":"Arriola-Villalobos","year":"2008","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.jaad.2015.07.053_bib28","first-page":"503","article-title":"Etanercept induced hidradenitis suppurativa","volume":"146","author":"Pellegrino","year":"2011","journal-title":"G Ital Dermatol Venereol"},{"key":"10.1016\/j.jaad.2015.07.053_bib29","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2165\/11599850-000000000-00000","article-title":"Leukaemic transformation in patients with haematological disease receiving tumour necrosis factor inhibitors","volume":"32","author":"Ferrer-Marin","year":"2012","journal-title":"Clin Drug Investig"},{"issue":"suppl 5","key":"10.1016\/j.jaad.2015.07.053_bib30","doi-asserted-by":"crossref","first-page":"v38","DOI":"10.1093\/rheumatology\/kes114","article-title":"Assessing the safety of biologic agents in patients with rheumatoid arthritis","volume":"51","author":"Rubbert-Roth","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2015.07.053_bib31","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/pds.2046","article-title":"Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data","volume":"20","author":"Askling","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jaad.2015.07.053_bib32","doi-asserted-by":"crossref","DOI":"10.1001\/jamadermatol.2015.0718","article-title":"Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","author":"Kalb","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2015.07.053_bib33","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/bjd.12105","article-title":"Impact of Toll-like receptor-4 and tumour necrosis factor gene polymorphisms in patients with hidradenitis suppurativa","volume":"168","author":"Savva","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2015.07.053_bib34","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1111\/j.1524-4725.2009.01214.x","article-title":"Randomized control trial for the treatment of hidradenitis suppurativa with a neodymium-doped yttrium aluminium garnet laser","volume":"35","author":"Tierney","year":"2009","journal-title":"Dermatol Surg"},{"key":"10.1016\/j.jaad.2015.07.053_bib35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/archdermatol.2010.245","article-title":"Histopathologic study of hidradenitis suppurativa following long-pulsed 1064-nm Nd:YAG laser treatment","volume":"147","author":"Xu","year":"2011","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2015.07.053_bib36","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.jaad.2008.11.911","article-title":"Hidradenitis suppurativa: a comprehensive review","volume":"60","author":"Alikhan","year":"2009","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2015.07.053_bib37","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1111\/j.1365-2133.2003.05663.x","article-title":"Infliximab for hidradenitis suppurativa","volume":"149","author":"Sullivan","year":"2003","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2015.07.053_bib38","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.jaad.2006.07.027","article-title":"Infliximab for severe hidradenitis suppurativa: transient clinical efficacy in 7 consecutive patients","volume":"56","author":"Fardet","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2015.07.053_bib39","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1159\/000102032","article-title":"Infliximab for the treatment of hidradenitis suppurativa","volume":"215","author":"Fernandez-Vozmediano","year":"2007","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2015.07.053_bib40","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/j.1365-2230.2006.02272.x","article-title":"Variable response of hidradenitis suppurativa to infliximab in four patients","volume":"32","author":"Usmani","year":"2007","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2015.07.053_bib41","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/j.1365-2133.2007.08332.x","article-title":"Long-term efficacy of a single course of infliximab in hidradenitis suppurativa","volume":"158","author":"Mekkes","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2015.07.053_bib42","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/j.1440-0960.2010.00623.x","article-title":"Hidradenitis suppurativa responding to treatment with infliximab","volume":"51","author":"Lasocki","year":"2010","journal-title":"Australas J Dermatol"},{"key":"10.1016\/j.jaad.2015.07.053_bib43","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2340\/00015555-1025","article-title":"Efficacy of infliximab for hidradenitis suppurativa: assessment of clinical and biological inflammatory markers","volume":"91","author":"Delage","year":"2011","journal-title":"Acta Derm Venereol"},{"key":"10.1016\/j.jaad.2015.07.053_bib44","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1684\/ejd.2012.1795","article-title":"Efficacy and\u00a0tolerance of prolonged infliximab treatment of moderate-to-severe forms of hidradenitis suppurativa","volume":"22","author":"Lesage","year":"2012","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.jaad.2015.07.053_bib45","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3109\/09546634.2012.683767","article-title":"Long-term efficacy of infliximab in hidradenitis suppurativa","volume":"23","author":"Paradela","year":"2012","journal-title":"J Dermatolog Treat"},{"key":"10.1016\/j.jaad.2015.07.053_bib46","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000343221","article-title":"Failure of anti-interleukin-1 therapy in severe hidradenitis suppurativa: a case report","volume":"226","author":"van der Zee","year":"2013","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2015.07.053_bib47","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1111\/bjd.13292","article-title":"Two cases of severe hidradenitis suppurativa with failure of anakinra therapy","volume":"172","author":"Menis","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2015.07.053_bib48","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jaad.2013.09.044","article-title":"An open-label study of anakinra for the treatment ofmoderate to severe hidradenitis suppurativa","volume":"70","author":"Leslie","year":"2014","journal-title":"J Am Acad Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962215020010?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962215020010?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:36:54Z","timestamp":1759271814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962215020010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0190962215020010"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2015.07.053","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of hidradenitis suppurativa with biologic medications","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2015.07.053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Published by Mosby, Inc.","name":"copyright","label":"Copyright"}]}}